Print

AVEG 026

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) February 06, 1996
ALVAC vCP300,rgp120/HIV-1 SF-2 Canarypox env, gag, pol additional CTL epitopes B; Protein Env gp120 B SF-2
ALVAC vCP300 Viral Vector - Pox
rgp120/HIV-1 SF-2 Protein
USA 140
NCT00001072
http://www.clinicaltrials.gov/ct2/show/NCT00001072